Oncternal Therapeutics, Inc. (ONCT)
Dec 3, 2024 - ONCT trading suspended
0.5266
-0.1670 (-24.12%)
Inactive · Last trade price on Dec 2, 2024
Oncternal Therapeutics Stock Forecast
ONCT's stock price has decreased by -92.3% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Oncternal Therapeutics stock had an average target of 10, with a low estimate of 2.00 and a high estimate of 18.
Price Target: $10 (+1,798.97%)
Analyst Consensus: Buy
No price target forecast data available
* Price targets were last updated on Sep 12, 2024.
Analyst Ratings
The average analyst rating for Oncternal Therapeutics stock from 3 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Northland Capital Markets | Northland Capital Markets | Buy → Hold Downgrades $2 | Buy → Hold | Downgrades | $2 | +279.79% | Sep 12, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $19 → $18 | Strong Buy | Maintains | $19 → $18 | +3,318.15% | Aug 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +3,508.05% | Jul 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +3,508.05% | May 31, 2024 |
Financial Forecast
Revenue This Year
1.68M
from 785.00K
Increased by 113.76%
Revenue Next Year
612.00K
from 1.68M
Decreased by -63.53%
EPS This Year
-12.12
from -13.43
EPS Next Year
-10.46
from -12.12
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 2.0M | 630,000 | |
| Avg | 1.7M | 612,000 | |
| Low | 1.3M | 588,000 |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 156.8% | -62.5% | |
| Avg | 113.8% | -63.5% | |
| Low | 71.1% | -65.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -11.91 | -10.76 | |
| Avg | -12.12 | -10.46 | |
| Low | -12.18 | -10.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.